🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Adjuvanted trivalent influenza virus vaccine (aTIV)

Found 14 matching trials

CT18 Infant Influenza Priming Study in Vaccine Naive Infants

PHASE2

This study evaluates whether priming influenza naive infants, age six to 23...

Status

Completed

Location

Vaccine Evaluation Center, BC Children's Hospital

Start Date

2018-11-01

Trial ID

NCT03669627

Treatments Being Tested

aTIV Primer QIV Primer aTIV Booster QIV Booster

Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, Including MF59C.1 Adjuvant, in Healthy Adults ≥65 Years of Age

PHASE2

The present study is designed to confirm the safety and immunogenicity of t...

Status

Completed

Location

Antwerp University Centre for the Evaluation of Vaccination

Start Date

2013-07

Trial ID

NCT01879540

Treatments Being Tested

aTIV

A Post-marketing Study to Monitor the Safety of a MF59-adjuvanted Influenza Vaccine Administered in Korean Subjects Aged 65 Years or Older

PHASE4

This study will evaluate the safety of an influenza (flu) vaccine in Korean...

Status

Completed

Location

KeeTaek Kim internal medicine Clinic

Start Date

2010-10

Trial ID

NCT01222403

Treatments Being Tested

Fluad_MF59-adjuvanted trivalent influenza subunit vaccine Vantaflu_MF59-adjuvanted trivalent influenza subunit vaccine

Safety and Immunogenicity of Different Formulations of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects 65 Years of Age and Above

PHASE1

In this study, the safety and immunogenicity of the current formulation of ...

Status

Completed

Location

PAREXEL Early Phase Clinical Unit

Start Date

2014-06

Trial ID

NCT02126761

Treatments Being Tested

Adjuvanted, trivalent subunit influenza vaccine Adjuvant level modified adjuvanted, trivalent subunit influenza vaccine Antigen level modified adjuvanted, trivalent subunit influenza vaccine Antigen and adjuvant level modified adjuvanted, trivalent subunit influenza vaccine

Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects

PHASE3

The present study, phase III, randomized, controlled, observer-blind, multi...

Status

Completed

Location

Tampere Vaccine Research Clinic (15 sites)

Start Date

2008-10

Trial ID

NCT00841763

Treatments Being Tested

Placebo (PL)Trivalent influenza virus vaccine (TIV)Adjuvanted monovalent influenza virus vaccine (aH5N1)Adjuvanted trivalent influenza virus vaccine (aTIV)

Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects

PHASE3

The present phase III study aims to evaluate the safety and immunogenicity ...

Status

Completed

Location

301, Tatum Highlands Medical Associates PLLC, 26224 N Tatum Blvd 15A

Start Date

2010-08

Trial ID

NCT01162122

Treatments Being Tested

MF59 adjuvanted trivalent subunit influenza vaccine (aTIV)Non-adjuvanted trivalent subunit influenza vaccine (TIV)

ADITEC FLU 2 STUDY: Understanding the Genetics Basis for Immune Responses to Flu Vaccines in Children and Adults

PHASE2

Influenza infection is related to significant morbidity and mortality in ch...

Status

Completed

Location

Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine

Start Date

2015-08

Trial ID

NCT02529904

Treatments Being Tested

MF59 - ATIV

Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to < 72 Months of Age

PHASE3

This Study Aims to Evaluate the Safety, Tolerability, and Immunogenicity of...

Status

Completed

Location

401 Paideia Jeronimo Salguero 2835 Piso 1

Start Date

2011-04

Trial ID

NCT01346592

Treatments Being Tested

Trivalent split influenza vaccine (TIV)MF59-adjuvanted trivalent influenza vaccine (aTIV)Licensed comparator trivalent split influenza vaccine (comparator TIV)

A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age

PHASE3

This Phase 3 study is a randomized, observer-blind study of MF59-adjuvanted...

Status

Completed

Location

84046-Accel Research Sites - Birmingham

Start Date

2023-10-23

Trial ID

NCT06087640

Treatments Being Tested

aQIV or aTIV QIV or TIV

Safety and Immunogenicity of an Adjuvanted Trivalent Influenza Vaccine in Children 6 to <72 Months of Age in Mexico.

PHASE3

The administration of adjuvanted Trivalent Influenza Vaccine (aTIV) has com...

Status

Completed

Location

03, Centro Médico Universitario

Start Date

2014-10

Trial ID

NCT02255279

Treatments Being Tested

Adjuvanted Trivalent Influenza Vaccine, 1 dose for non-naive subjects (day 1), two doses for naive subjects (day 1 and day 29)Non-adjuvanted Trivalent Influenza Vaccine, 1 dose for non-naive subjects (day 1), two doses for naive subjects (day 1 and day 29).

Previous Next